Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?

SABCS - T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2+ MBC

SABCS - Racial Disparity in Pro-metastatic T-MEM Among Women With Residual BC After NAC

SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC

SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation